marium Imatinib Tablets IP 400 mg is a prescription oral oncology medicine identified as containing Imatinib 400 mg per tablet.

Imatinib is a targeted anticancer medicine classified as a tyrosine kinase inhibitor (TKI).

It inhibits several tyrosine kinases involved in cancer-cell growth and survival, including BCR-ABL, KIT and platelet-derived growth factor receptors (PDGFR).

Imatinib is an established treatment option in selected settings involving Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), gastrointestinal stromal tumors (GIST) and certain other kinase-driven malignancies.

The stated 400 mg tablet strength does not establish the prescribed daily dose for every patient. Different indications and disease phases use different treatment schedules and may require dose adjustments.

The exact manufacturer, pack size, tablet composition, storage conditions and approved indications of Imarium must be verified from its approved Indian product documentation.

The product name includes IP (Indian Pharmacopoeia). Compliance with the applicable pharmacopoeial standard must be supported by manufacturer documentation.

Marketed by Essentials Emporium Enterprises, Imarium is listed within the oncology pharmaceutical category for hospitals, cancer treatment centres and authorized pharmaceutical buyers.

Key Product Features